Aligos Therapeutics effects 1-for-25 reverse stock split to meet Nasdaq listing requirement

Aligos Therapeutics, Inc.

Reverse split at 1-for-25 effective 12:01 a.m. ET on August 19, 2024; trading symbol ALGS unchanged.
Split intended to bring company into compliance with Nasdaq minimum bid price for continued listing.
Every 25 pre-split shares reclassified into one new share; par value unchanged at $0.0001.
No fractional shares issued; holders entitled to cash payment based on August 16, 2024 closing price.
Board approved split on July 24, 2024; final ratio set by Reverse Split Committee on August 6, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.